Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Disrupted bile acid regulation and accumulation in the liver can contribute to progressive liver damage and fibrosis. However, the effects of bile acids on the activation of hepatic stellate cells (HSCs) remain unclear. This study investigated the effects of bile acids on HSC activation during liver fibrosis, and examined the underlying mechanisms. Methods: The immortalized HSCs, LX-2 and JS-1cells were used for the in vitro study. in vitro, the adeno-associated viruses adeno-associated virus-sh-S1PR2 and JTE-013 were used to pharmacologically inhibit the activity of S1PR2 in a murine model of fibrosis induced by a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet. Histological and biochemical analyses were performed to study the involvement of S1PR2 in the regulation of fibrogenic factors as well as the activation properties of HSCs. Results: S1PR2 was the predominant S1PR expressed in HSCs and was upregulated during taurocholic acid (TCA) stimulation and in cholestatic liver fibrosis mice. TCA-induced HSC proliferation, migration and contraction and extracellular matrix protein secretion were inhibited by JTE-013 and a specific shRNA targeting S1PR2 in LX-2 and JS-1 cells. Meanwhile, treatment with JTE-013 or S1PR2 deficiency significantly attenuated liver histopathological injury, collagen accumulation, and the expression of fibrogenesis-associated genes in mice fed a DDC diet. Furthermore, TCAmediated activation of HSCs through S1PR2 was closely related to the yes-associated protein (YAP) signaling pathway via p38 mitogen-activated protein kinase (p38 MAPK). Conclusions: TCA-induced activation of the S1PR2/p38 MAPK/YAP signaling pathways plays a vital role in regulating HSC activation, which might be therapeutically relevant for targeting cholestatic liver fibrosis.
Abstract
Background/Aims: Disrupted bile acid regulation and accumulation in the liver can contribute to progressive liver damage and fibrosis. However, the effects of bile acids on the activation of hepatic stellate cells (HSCs) remain unclear. This study investigated the effects of bile acids on HSC activation during liver fibrosis, and examined the underlying mechanisms. Methods: The immortalized HSCs, LX-2 and JS-1cells were used for the in vitro study. in vitro, the adeno-associated viruses adeno-associated virus-sh-S1PR2 and JTE-013 were used to pharmacologically inhibit the activity of S1PR2 in a murine model of fibrosis induced by a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) diet. Histological and biochemical analyses were performed to study the involvement of S1PR2 in the regulation of fibrogenic factors as well as the activation properties of HSCs. Results: S1PR2 was the predominant S1PR expressed in HSCs and was upregulated during taurocholic acid (TCA) stimulation and in cholestatic liver fibrosis mice. TCA-induced HSC proliferation, migration and contraction and extracellular matrix protein secretion were inhibited by JTE-013 and a specific shRNA targeting S1PR2 in LX-2 and JS-1 cells. Meanwhile, treatment with JTE-013 or S1PR2 deficiency significantly attenuated liver histopathological injury, collagen accumulation, and the expression of fibrogenesis-associated genes in mice fed a DDC diet. Furthermore, TCAmediated activation of HSCs through S1PR2 was closely related to the yes-associated protein (YAP) signaling pathway via p38 mitogen-activated protein kinase (p38 MAPK). Conclusions: TCA-induced activation of the S1PR2/p38 MAPK/YAP signaling pathways plays a vital role in regulating HSC activation, which might be therapeutically relevant for targeting cholestatic liver fibrosis.
참고문헌 (48)
- Ibrahim SH, "Cholestatic liver diseases of genetic etiology : Advances and controversies", Hepatology, 75, pp.1627~1646 (2022)
- Lee YA, "Pathobiology of liver fibrosis : a translational success story", Gut, 64, pp.830~841 (2015)
- Pinzani M, "Pathophysiology of liver fibrosis", Dig Dis, 33, pp.492~497 (2015)
- Parola M, "Liver fibrosis : Pathophysiology, pathogenetic targets and clinical issues", Mol Aspects Med, 65, pp.37~55 (2019)
- Wang X, "Serum bile acids are associated with pathological progression of hepatitis B-induced cirrhosis", J Proteome Res, 15, pp.1126~1134 (2016)
- Horvatits T, "Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis", Liver Int, 37, pp.224~231 (2017)
- Liu Z, "Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis : evidence from a human metabolomic study and in vitro experiments", BMC Gastroenterol, 18, pp.112~ (2018)
- Svegliati-Baroni G, "Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor", Gastroenterology, 128, pp.1042~1055 (2005)
- Fiorucci S, "The pharmacology of bile acids and their receptors", Handb Exp Pharmacol, 256, pp.3~18 (2019)
- Kunst RF, "Insufficient evidence for NTCP activity in stellate cells", Gut, 71, pp.2140~2141 (2021)
- Green CD, "Sphingolipids in metabolic disease : The good, the bad, and the unknown", Cell Metab, 33, pp.1293~1306 (2021)
- Rohrbach T, "Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology", Crit Rev Biochem Mol Biol, 52, pp.543~553 (2017)
- Wang Y, "The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice", Hepatology, 65, pp.2005~2018 (2017)
- Luo L, "Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents", Toxicol Sci, 137, pp.12~25 (2014)
- Studer E, "Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes", Hepatology, 55, pp.267~276 (2012)
- Lian N, "Curcumin regulates cell fate and metabolism by inhibiting hedgehog signaling in hepatic stellate cells", Lab Invest, 95, pp.790~803 (2015)
- Maruyama T, "Identification of membrane-type receptor for bile acids(M-BAR)", Biochem Biophys Res Commun, 298, pp.714~719 (2002)
- Kawamata Y, "A G protein-coupled receptor responsive to bile acids", J Biol Chem, 278, pp.9435~9440 (2003)
- Martin K, "PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis", Nat Commun, 7, pp.12502~ (2016)
- Spiegel S, "The outs and the ins of sphingosine1-phosphate in immunity", Nat Rev Immunol, 11, pp.403~415 (2011)
- Friedman SL, "Hepatic stellate cells : protean, multifunctional, and enigmatic cells of the liver", Physiol Rev, 88, pp.125~172 (2008)
- Schwabe RF, "Mechanisms of fibrosis development in nonalcoholic steatohepatitis", Gastroenterology, 158, pp.1913~1928 (2020)
- Tsuchida T, "Mechanisms of hepatic stellate cell activation", Nat Rev Gastroenterol Hepatol, 14, pp.397~411 (2017)
- Nishio T, "Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice", J Hepatol, 71, pp.573~585 (2019)
- Sommerfeld A, "Bile acid-induced epidermal growth factor receptor activation in quiescent rat hepatic stellate cells can trigger both proliferation and apoptosis", J Biol Chem, 284, pp.22173~22183 (2009)
- Kageyama Y, "Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents", Hepatology, 56, pp.1427~1438 (2012)
- Salhab A, "Sodium+", taurocholate cotransporting polypeptide as target therapy for liver fibrosis, 2022, pp.71, 1373~1385
- Halilbasic E, "Bile acid transporters and regulatory nuclear receptors in the liver and beyond", J Hepatol, 58, pp.155~168 (2013)
- Goutam K, "Structural basis of sodium-dependent bile salt uptake into the liver", Nature, 606, pp.1015~1020 (2022)
- Yan H, "Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus", Elife, 1, pp.e00049~ (2012)
- Cheng D, "Clinical effects of NTCP-inhibitor myrcludex B", J Viral Hepat, 28, pp.852~858 (2021)
- Bogomolov P, "Treatment of chronic hepatitis D with the entry inhibitor myrcludex B : First results of a phase Ib", IIa study, 2016, pp.65, 490~498
- Nevens F, "A placebo-controlled trial of obeticholic acid in primary biliary cholangitis", N Engl J Med, 375, pp.631~643 (2016)
- Younossi ZM, "Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 394, pp.2184~2196 (2019)
- Zhou J, "Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis", Acta Pharm Sin B, 9, pp.526~536 (2019)
- Kjærgaard K, "Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis", J Hepatol, 74, pp.58~65 (2021)
- Huang S, "A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage", Metabolism, 120, pp.154797~ (2021)
- Fiorucci S, "A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis", J Pharmacol Exp Ther, 314, pp.584~595 (2005)
- Li J, "Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells", Mol Pharmacol, 80, pp.191~200 (2011)
- Fiorucci S, "The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis", Gastroenterology, 127, pp.1497~1512 (2004)
- Verbeke L, "Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats", Hepatology, 59, pp.2286~2298 (2014)
- Fickert P, "Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts", Am J Pathol, 175, pp.2392~2405 (2009)
- Zhou J, "SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis", Nat Commun, 11, pp.240~ (2020)
- Mannaerts I, "The Hippo pathway effector YAP controls mouse hepatic stellate cell activation", J Hepatol, 63, pp.679~688 (2015)
- He Y, "YAP regulates periodontal ligament cell differentiation into myofibroblast interacted with RhoA", ROCK pathway, 2019, pp.234, 5086~5096
- Du K, "Hedgehog-YAP signaling pathway regulates glutaminolysis to control activation of hepatic stellate cells", gastroenterology, 154, pp.1465~1479 (2018)
- Moya IM, "Hippo-YAP", TAZ signalling in organ regeneration and regenerative medicine, 2019, pp.20, 211~226
- Shue YT, "A conserved YAP", Notch, Nat Commun, pp.2022, 13[DOI]